Skip to content
Research Article Open access CC BY 4.0

Myocardial Infarction in a Young Patient with Chronic Myeloid Leukemia after Nilotinib Use

Neila Fathallah, Kmira Zahra, Rania Bouneb, Mohamed Mahjoub, Wafa Guetari, Monia Zaier, Chaker Ben Salem, Abderrahim Khelif

International Journal of Medical and Pharmaceutical Case Reports · pp. 1–5 · Published 11 Sep 2016

10.9734/IJMPCR/2016/28909

Abstract

Nilotinib is an analog of imatinib increasingly used for the treatment of imatinib-resistant chronic myeloid leukemia. It has been considered a well-tolerated drug with little side effects. The most common adverse effects to nilotinib are skin rash, pruritus, headache, nausea, and fatigue. Nilotinib-induced vascular events are rare, including peripheral artery occlusive disease, Raynaud syndrome, cerebrovascular accidents. Myocardial infarction has rarely been reported. In this paper, we describe the case of a 37-year-old female who developed a severe myocardial infarction after nilotinib use. There are two different vascular events reported with nilotinib: A progressively worsening of preexistent occluding vascular lesions and vasospastic events. In our patient, myocardial infarction seems to be secondary to severe coronary occlusive event. Nilotinib might facilitate the development of vascular events in patients with preexisting risk factors. However several patients have been shown to experience such events in the absence of any cardiovascular risk factor. The mechanism of nilotinib-induced myocardial infarction is still controversial. It is reported to be induced via mitochondrial damage, a negative effect of the substance on pre-existing atherosclerotic changes or ischaemic processes. Our report emphasizes the importance of early detection and evaluation of cardiotoxicity in order to prevent fatal consequences of such an adverse event even in young patients.

Philadelphia chromosome chronic myeloid leukemia nilotinib myocardial infarction

References (12)

  1. 1 Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL [DOI]
  2. 2 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance [DOI]
  3. 3 Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia [DOI]
  4. 4 Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib [DOI]
  5. 5 Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results [DOI]
  6. 6 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia [DOI]
  7. 7 Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib [DOI]
  8. 8 Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling [DOI]
  9. 9 Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) [DOI]
  10. 10 Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib [DOI]
  11. 11 Clinical cardiac safety profile of nilotinib [DOI]
  12. 12 Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

8

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.